DYV700
/ Dyve Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 29, 2022
Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)
(clinicaltrials.gov)
- P2 | N=284 | Completed | Sponsor: Dyve Biosciences, Inc. | Recruiting ➔ Completed | Trial primary completion date: Feb 2021 ➔ May 2021
Trial completion • Trial primary completion date • Gout • Inflammatory Arthritis • Pain • Rheumatology
May 31, 2021
[VIRTUAL] Dyve Biosciences
(BIO 2021)
- "Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20- center, 100-patient, Phase 2 clinical study for the treatment of acute gout...It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs."
Gout • Inflammatory Arthritis • Rheumatology
February 27, 2020
Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)
(clinicaltrials.gov)
- P2; N=300; Recruiting; Sponsor: Dyve Biosciences, Inc.; Enrolling by invitation ➔ Recruiting
Clinical • Enrollment status
February 24, 2020
Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)
(clinicaltrials.gov)
- P2; N=300; Enrolling by invitation; Sponsor: Dyve Biosciences, Inc.; Not yet recruiting ➔ Enrolling by invitation
Clinical • Enrollment open
1 to 4
Of
4
Go to page
1